Tag archive for ‘testosterone replacement market’
Antares: Thoughts on FDA Briefing Documents for September 17th Advisory Committee Meeting on Testosterone Replacement Products (ATRS, $2.14, Buy)
The FDA does not appear to be concerned about cardiovascular risk with testosterone replacement products so this is a major positive. The FDA is asking the panel to consider if these products are used too much in unapproved indications. The testosterone replacement market has shrunk significantly in 2014 due to the cardiovascular safety issue. There […]